Adynxx (Adynxx) Net Margin % : 0.00% (As of Sep. 2019)

View and export this data going back to 1998. Start your Free Trial

What is Adynxx Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Adynxx's Net Income for the three months ended in Sep. 2019 was $-1.90 Mil. Adynxx's Revenue for the three months ended in Sep. 2019 was $0.00 Mil. Therefore, Adynxx's net margin for the quarter that ended in Sep. 2019 was 0.00%.

The historical rank and industry rank for Adynxx's Net Margin % or its related term are showing as below:

ADYX's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -162.58
* Ranked among companies with meaningful Net Margin % only.

Adynxx Net Margin % Historical Data

The historical data trend for Adynxx's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Net Margin % Chart

Adynxx Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Net Margin %

Get a 7-Day Free Trial

-531.65

-213.66

-173.33

-1,273.25

-379.83

Adynxx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Net Margin %	Get a 7-Day Free Trial															-216.67	-280.43	-671.32	-	-

Competitive Comparison of Adynxx's Net Margin %

For the Biotechnology subindustry, Adynxx's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adynxx's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's Net Margin % distribution charts can be found below:

* The bar in red indicates where Adynxx's Net Margin % falls into.

Adynxx Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Adynxx's Net Margin for the fiscal year that ended in Dec. 2018 is calculated as

Net Margin	=	Net Income (A: Dec. 2018 )	/	Revenue (A: Dec. 2018 )
	=	-8.417	/	2.216
	=	-379.83 %

Adynxx's Net Margin for the quarter that ended in Sep. 2019 is calculated as

Net Margin	=	Net Income (Q: Sep. 2019 )	/	Revenue (Q: Sep. 2019 )
	=	-1.895	/	0
	=	%

Adynxx (OTCPK:ADYX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Adynxx Net Margin % Related Terms

Thank you for viewing the detailed overview of Adynxx's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adynxx (Adynxx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (OTCPK:ADYX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Pine Street, Suite 500, San Francisco, CA, USA, 94111

Website

http://www.adynxx.com

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Executives

Gregory J. Flesher	director	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Donald C. Manning	officer: CHIEF MEDICAL OFFICER	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Domain Partners Viii, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber	director	C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian K Halak	10 percent owner	C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo	10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair	10 percent owner	5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu	10 percent owner
Dennis Podlesak	director	C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Tpg Group Holdings (sbs) Advisors, Inc.	10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
James G Coulter	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
David Bonderman	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102